|
Destiny Pharma PLC on Monday announced positive data for its lead drug exeporfinium chloride, known as XF-73, and to be presented in Birmingham in late September. The Brighton, England-based clinical phase biotechnology company focused on developing novel anti-infectives said data from a study showed XF-73 reduced MRSA infection within burn wound tissue by up to 99.99% compared to the placebo treatment. The reduction occurred following a single topical application of 25, 50 or 100 microgrammes of XF-73. MRSA stands for methicillin-resistant Staphylococcus aureus and can cause life-threatening sepsis, which has a high mortality rate. Chief Scientific Officer Bill Love said: ‘These results from an in vivo burn wound infection model provide clear evidence that XF-73 can significantly reduce the risk, or even eliminate MRSA from reaching the bloodstream and causing sepsis. It is seen as a significant result for the continued development of our XF-73 dermal product.’ Destiny Pharma shares fell 4.2% to 2.30 pence each on Monday morning in London. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
